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AbstrACt
Objectives To evaluate the extent to which patients with 
type 2 diabetes discontinue metformin therapy when 
initiating second- line treatment and factors associated 
with metformin discontinuation, using baseline data from 
the DISCOVER study programme.
Design DISCOVER is a 3- year, prospective, observational 
study programme including data from 38 countries across 
6 continents from 2014 to 2019.
setting Primary and secondary healthcare centres, 
hospitals and specialist diabetes centres in both urban and 
rural locations.
Participants A total of 15 992 patients with type 2 
diabetes initiating second- line glucose- lowering therapy.
Primary and secondary outcome measures The 
proportion of patients who discontinued metformin as a 
second- line therapy and the factors associated with this 
treatment change.
results Of the 14 668 patients (from 37 countries) with 
valid treatment data, 11 837 (80.7%) received metformin 
as first- line glucose- lowering therapy; 8488 (71.7%) 
received metformin monotherapy and 3349 (28.3%) 
received metformin as part of a combination therapy. 
Overall, treatment with metformin was discontinued in 
15.1% (1782) of patients who received first- line metformin 
(14.1% (1194) and 17.6% (588) in those who received 
metformin as monotherapy and as part of a combination, 
respectively); this proportion varied across regions from 
6.9% (54) in Africa to 20.6% (628) in South- East Asia. 
On metformin discontinuation, 73.6% (1311) of patients 
received a non- insulin monotherapy at second line. 
Factors associated with an increased odds of metformin 
discontinuation were older age (≥75 years) and having 
a history of chronic kidney disease. The probability of 
metformin monotherapy discontinuation was lower in 
patients from Africa than in those from Europe.
Conclusions A substantial number of patients 
discontinued taking metformin when beginning second- 
line therapy. Most of these patients subsequently received 
a non- insulin monotherapy at second line, in contradiction 
to international guidelines and potentially leaving them 
at an increased risk of hyperglycaemia and associated 
adverse outcomes.
trial registration numbers NCT02322762 and 
NCT02226822.
IntrODuCtIOn
Current international clinical guidelines 
for the treatment of patients with type 2 
diabetes recommend the use of metformin 
for most patients as the first- line pharmaco-
logical treatment in conjunction with life-
style changes to control glycaemic levels.1–6 If 
glycated haemoglobin (HbA1c) levels remain 
uncontrolled, guidelines recommend the 
addition of a second glucose- lowering agent 
to ongoing metformin therapy. The propor-
tion of patients who discontinue metformin 
treatment, and reasons for discontinuation, 
have not previously been assessed on a global 
scale.
DISCOVER is a 3- year, global, prospec-
tive, non- interventional study programme 
conducted simultaneously in 38 countries 
strengths and limitations of this study
 ► The study involved countries from which limited 
data are available on type 2 diabetes.
 ► The standardised case report form allowed compar-
isons to be made between regions.
 ► The diversity of sites provides a picture of global 
healthcare settings.
 ► Quality of care in some countries may still be over- 
represented or under- represented.
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across 6 continents, recruiting patients with type 2 diabetes 
initiating a second- line glucose- lowering therapy (defined 
as adding a glucose- lowering drug or switching between 
therapies). Comprehensive data were collected using a 
standardised electronic case report form. The primary 
study objectives are to describe disease management 
patterns and associated clinical and health- related quality 
of life outcomes.7 In this study we aimed to evaluate the 
extent to which patients discontinue treatment with 
metformin when initiating a second- line glucose- lowering 
therapy. Factors associated with metformin discontinua-
tion were also assessed.
MethODs
The methods for the DISCOVER study programme 
have been described in detail elsewhere7 and are briefly 
summarised below.
study design
The DISCOVER study programme comprises two similar, 
3- year, non- interventional, prospective studies conducted 
in parallel in 38 countries and including a total of 15 992 
patients: DISCOVER in 37 countries and J- DISCOVER 
in Japan. Countries are grouped into regions according 
to WHO categories:8 Africa (Algeria and South Africa); 
Americas (Argentina, Brazil, Canada, Colombia, Costa 
Rica, Mexico and Panama); South- East Asia (India and 
Indonesia); Europe (Austria, Czech Republic, Denmark, 
France, Italy, Netherlands, Norway, Poland, Russia, 
Spain, Sweden and Turkey); the Eastern Mediterranean 
(Bahrain, Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi 
Arabia, Tunisia and United Arab Emirates); and the 
Western Pacific (Australia, China, Japan, Malaysia, South 
Korea and Taiwan).
The study protocols were approved by the relevant 
clinical research ethics committees in each country and 
institutional review boards at each site (online supple-
mentary appendix), and complied with the Declaration 
of Helsinki, the International Conference on Harmonisa-
tion Guideline for Good Clinical Practice, and the local 
regulations for clinical research.
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting or dissemination of our research.
site and investigator selection
For each participating country, characteristics of the 
physicians and clinical centres involved in the manage-
ment of patients with type 2 diabetes were first assessed 
by conducting literature searches and interviewing key 
local diabetes experts, who acted as the national coor-
dinating investigators for the study. Information on the 
proportions of physicians by speciality (primary care prac-
titioners, diabetologists/endocrinologists, cardiologists 
and other specialities) and types of practices (primary 
care centres, specialised diabetes centres and different 
types of hospitals) in each country was collated. A list of 
sites that would match these characteristics as closely as 
possible was established for each country, and the sites 
were invited to participate. Approximately one- third of 
invited sites were able to participate and enrolled patients 
in the study.
Patient enrolment
Inclusion and exclusion criteria were kept to a minimum 
to reflect the diversity of patients treated in routine clin-
ical practice. Briefly, patients aged 18 years or older who 
had type 2 diabetes and who were initiating a second- 
line glucose- lowering therapy were eligible for inclusion 
if they were not pregnant, were not undergoing dialysis 
and did not have a history of renal transplant, and if 
their first- line therapy was not an injectable agent or a 
herbal remedy or natural medicine alone. Full inclusion 
and exclusion criteria can be found in online supplemen-
tary table S1. The study protocol stated that investigating 
physicians should invite consecutive eligible patients to 
enrol in the study. All participating patients provided 
written informed consent.
Data collection
Data were collected using a standardised electronic case 
report form and transferred to a central database via a web- 
based data capture system. Some data were extracted from 
existing electronic health records in Canada, Denmark, 
France, Norway and Sweden. In these countries, data not 
routinely captured in electronic medical records, such as 
the reason(s) for treatment change, were obtained by the 
investigators using a questionnaire that was linked back to 
patients’ medical records. Variables collected at baseline 
included physician and site characteristics, patient demo-
graphics, physiological parameters, laboratory test results 
including HbA1c level, change in glucose- lowering thera-
pies and reason(s) for change, comorbidities including 
microvascular and macrovascular diseases and co- medica-
tions. In line with the observational nature of the study, 
clinical variables such as HbA1c and/or fasting plasma 
glucose levels were measured and recorded in accor-
dance with routine clinical practice; data collection was 
not mandatory for any of the clinical variables.
statistical analysis
For the present analysis patients from China (n=1293) 
were excluded because complete data were not available 
at the time of publication. Patients were also excluded 
from the analysis if they had treatment information 
missing at baseline (n=4) or if they had metformin 
monotherapy recorded as both first- line and second- 
line therapy (n=27). Data from a total of 14 668 patients 
from DISCOVER were therefore assessed for this analysis. 
Descriptive data are reported as numbers and percent-
ages, with percentages calculated using the total number 
of patients with data available as the denominator. Mean 
(SD) values and across- region ranges (ARRs) are also 
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metformin discontinuation were assessed using hierar-
chical logistical models with country as a random effect 
and with baseline covariates (sex, age, body mass index, 
education level, time since diagnosis, HbA1c level, health 
insurance status, employment status, region and medical 
history: macrovascular complications, microvascular 
complications, chronic kidney disease (CKD) and minor 
or major hypoglycaemic events) as fixed effects. These 
covariates were selected a priori as clinically relevant vari-
ables that could potentially be associated with the odds of 
metformin discontinuation.
Median ORs (MORs) were calculated to describe 
country- level variance in the odds of metformin discon-
tinuation. The MOR is the median of the ORs obtained 
when comparing the odds of discontinuing metformin 
in an individual from a randomly selected country with 
that of another individual with identical baseline covari-
ates from another randomly selected country. The MOR 
was calculated by assessing the odds of metformin discon-
tinuation for all the selected pairs of individuals from 
different countries, with the individual from the country 
with the highest odds of metformin discontinuation as 
the numerator and the individual with the lowest odds 
of metformin discontinuation as the denominator. This 
calculation resulted in a distribution of ORs always ≥1. 
The MOR is the median value of this distribution.9 10 If 
the MOR was equal to 1, there would be no difference 
between countries in the probability of discontinuing 
metformin; the larger the MOR, the greater the vari-
ability in the probabilities of discontinuing metformin 
across countries. All statistical analyses were conducted 
using the SAS 9.4 statistical software system (SAS Institute 
Inc, Cary, North Carolina, USA).
results
Patient baseline characteristics
Of the 14 668 DISCOVER participants with valid treat-
ment data, 11 837 (80.7%) had received metformin (on 
its own or as part of a combination) as first- line treatment 
(table 1). Some variation in baseline characteristics of 
patients receiving metformin as a first- line therapy was 
seen across study regions (online supplementary file 2).
Among the patients who received first- line metformin, 
10 055 (84.9%, ARR: 79.4% to 93.1%) continued 
metformin at second line, while 1782 (15.1%, ARR: 6.9% 
to 20.6%) discontinued metformin. Most baseline char-
acteristics were similar between patients who continued 
and those who discontinued treatment. The proportion 
of patients with a history of microvascular complications 
was lower in patients continuing metformin (17.5%) 
than in those discontinuing metformin (21.6%). The 
proportion of patients with a history of CKD was also 
lower in patients continuing metformin (3.3%) than in 
those discontinuing metformin (6.6%). The proportion 
of patients with health insurance was higher in patients 
continuing metformin (75.9%) than in those discontin-
uing metformin (66.2%).
treatment patterns
Second- line treatment patterns for the 11 837 patients who 
had received metformin at first line are shown according 
to first- line treatment in table 2, and according to region 
in table 3. Of these patients, 8488 (71.7%) had received 
first- line metformin monotherapy. The remaining 3349 
patients (28.3%) had received metformin as part of a 
combination therapy, most commonly with a sulphony-
lurea (63.9%). First- line metformin was most commonly 
prescribed as a monotherapy in all study regions other 
than South- East Asia (table 3).
The proportion of patients who discontinued 
metformin varied substantially across study regions, from 
6.9% in Africa to 20.6% in South- East Asia (table 3). 
Among the 1782 patients (15.1%) who discontinued 
treatment with metformin (monotherapy or as part of 
a combination therapy), the most common second- line 
therapies were dipeptidyl peptidase-4 inhibitor mono-
therapies and sulphonylurea monotherapies (27.0% and 
20.3%, respectively).
reasons for changing therapy
Reasons for changing from first- line to second- line 
therapy (with or without metformin) are shown overall in 
table 4 and by region in online supplementary table S3. 
Lack of efficacy was the reason stated for changing therapy 
among 88.7% of patients (10 185/11 837) overall; 91.5% 
of patients (8928/10 055) who continued metformin 
therapy and 72.7% of patients (1257/1782) who discon-
tinued metformin therapy. Reasons for changing therapy 
also varied greatly across regions (online supplementary 
table S3). The proportions of patients who discontinued 
metformin for whom lack of efficacy was reported as a 
reason for treatment change ranged between 50.9% in 
the Americas and 94.4% in Africa.
Adverse effects were more commonly cited as a 
reason for changing therapy in patients who discon-
tinued metformin (16.8%) than in those who continued 
metformin (3.4%). Chronic kidney disease development 
was also more commonly cited as a reason for changing 
therapy in patients who discontinued metformin (4.7%) 
than in those who continued metformin (0.3%). Of the 
patients who discontinued metformin, the proportions of 
patients for whom adverse effects were cited as reasons for 
changing therapy ranged from 1.9% in Africa to 41.4% 
in the Americas; the proportions of patients for whom 
chronic disease development was given as a reason for 
changing therapy ranged from 0.0% in Africa to 10.8% 
in Europe.
Factors associated with metformin therapy discontinuation
Factors associated with increased or decreased odds of 
discontinuing metformin are shown in figure 1. Having 
CKD and being aged 75 years or older (vs <65 years) were 
associated with an increased odds of metformin discon-
tinuation, whether metformin was used as a monotherapy 
or as part of a combination. In addition, among patients 




arch 24, 2021 at T










pen: first published as 10.1136/bm





4 Khunti K, et al. BMJ Open 2020;10:e034613. doi:10.1136/bmjopen-2019-034613
Open access 
Table 1 Baseline characteristics of patients receiving a second- line therapy with or without metformin
Characteristic
Second- line therapy with 
MET n=10 055
Second- line therapy without 
MET n=1782 Overall N=11 837 P value
Proportion of patients, % 84.9 15.1 100
Sex, male, n (%) 5321 (52.9) 953 (53.5) 6274 (53.0) 0.574
  Missing, n 2 2 4
Age
  Years, mean (SD) 56.2 (11.6) 57.8 (12.1) 56.5 (11.7) 0.179
  ≤65 years, n (%) 7935 (78.9) 1333 (74.8) 9268 (78.3) 0.152
  66–75 years, n (%) 1704 (16.9) 327 (18.4) 2031 (17.2)
  ≥76 years, n (%) 416 (4.1) 122 (6.8) 538 (4.5)
  Missing, n 0 0 0
BMI, kg/m2, mean (SD) 30.0 (5.9) 29.7 (6.3) 30.0 (6.0) <0.001
  Missing, n 863 140 1003
HbA1c, %
  Mean(SD) 8.5 (1.7) 8.1 (1.8) 8.4 (1.7) 0.920
  <7.0, n (%) 1130 (13.9) 335 (25.5) 1465 (15.6) 0.829
  7.0 to <8.0, n (%) 2559 (31.6) 392 (29.9) 2951 (31.3)
  8.0 to <9.0, n (%) 2012 (24.8) 272 (20.7) 2284 (24.3)
  ≥9.0, n (%) 2404 (29.7) 314 (23.9) 2718 (28.9)
  Missing, n 1950 469 2419
Education level, n (%)
  No formal education 290 (3.2) 44 (2.7) 334 (3.1) <0.001
  Primary education (1–6 years) 1599 (17.5) 228 (14.0) 1827 (17.0)
  Secondary education (7–13 years) 4262 (46.7) 847 (52.0) 5109 (47.5)
  >13 years of education 2971 (32.6) 510 (31.3) 3481 (32.4)
  Missing, n 933 153 1086
Health insurance, n (%)
  Private 1576 (16.8) 256 (15.8) 1832 (16.6) <0.001
  Public/governmental 5288 (56.2) 767 (47.3) 6055 (54.9)
  Mixed 279 (3.0) 51 (3.1) 330 (3.0)
  No insurance 2264 (24.1) 549 (33.8) 2813 (25.5)
  Missing, n 648 159 807
Employed or self- employed, n (%) 4636 (49.2) 771 (45.9) 5407 (48.7) 0.573
  Missing 639 102 741
Medical history, n (%)
  Macrovascular complications 1380 (13.8) 259 (14.6) 1639 (13.9) 0.001
   Missing, n 31 7 38
  Microvascular complications 1755 (17.5) 384 (21.6) 2139 (18.1) 0.010
   Missing, n 12 3 15
  Chronic kidney disease, n (%) 329 (3.3) 117 (6.6) 446 (3.8) 0.831
   Stage 2 (eGFR 60–89 mL/min/1.73 m2) 181 (55.0) 52 (44.4) 233 (52.2) <0.001
   Stage 3 (eGFR 30–59 mL/min/1.73 m2) 91 (27.7) 50 (42.7) 141 (31.6)
   Stage 4 (eGFR 15–29 mL/min/1.73 m2) 6 (1.8) 8 (6.8) 14 (3.1)
   Stage 5 (eGFR <15 mL/min/1.73 m2) 6 (1.8) 0 (0.0) 6 (1.3)
   Stage unknown 45 (13.7) 7 (6.0) 52 (11.7)
   Missing, n 12 3 15
Time since diagnosis, years, mean (SD) 5.6 (5.1) 5.3 (4.8) 5.6 (5.1) <0.001
  Missing, n 200 42 242
Data are reported as n (%), unless otherwise stated. Percentages were calculated for all patients with data available; patients with missing data were excluded.
P values were calculated using either a Student’s t- test (continuous variables), χ2 test (categorical variables) or Fisher’s exact test (categorical variables). P values <0.05 
were considered statistically significant.
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Table 2 Second- line therapies in patients receiving metformin (as monotherapy or as part of a combination treatment) as a 


















Second- line therapy with MET 7294 (85.9) 1739 (81.3) 406 (83.0) 184 (84.8) 432 (85.7) 10 055 (84.9)
  MET monotherapy 0 (0.0) 22 (1.0) 9 (1.8) 2 (0.9) 2 (0.4) 35 (0.3)
  MET+SU 2549 (30.0) 137 (6.4) 23 (4.7) 2 (0.9) 31 (6.2) 2742 (23.2)
  MET+DPP- 4i 2780 (32.8) 243 (11.4) 58 (11.9) 3 (1.4) 56 (11.1) 3140 (26.5)
  MET+SU+DPP- 4i 135 (1.6) 588 (27.5) 131 (26.8) 29 (13.4) 37 (7.3) 920 (7.8)
  MET+insulin* 288 (3.4) 214 (10.0) 33 (6.7) 59 (27.2) 79 (15.7) 673 (5.7)
  MET+other(s)† 1542 (18.2) 535 (25.0) 152 (31.1) 89 (41.0) 227 (45.0) 2545 (21.5)
Second- line therapy without 
MET
1194 (14.1) 400 (18.7) 83 (17.0) 33 (15.2) 72 (14.3) 1782 (15.1)
  SU monotherapy 322 (3.8) 13 (0.6) 22 (4.5) 1 (0.5) 3 (0.6) 361 (3.0)
  DPP- 4i monotherapy 376 (4.4) 93 (4.3) 6 (1.2) 0 (0.0) 7 (1.4) 482 (4.1)
  Other monotherapy† 224 (2.6) 183 (8.6) 20 (4.1) 14 (6.5) 27 (5.4) 468 (4.0)
  Insulin* 61 (0.7) 52 (2.4) 13 (2.7) 9 (4.1) 13 (2.6) 148 (1.3)
  Other combinations without 
MET
211 (2.5) 59 (2.8) 22 (4.5) 9 (4.1) 22 (4.4) 323 (2.7)
Data are reported as n (%). Percentages were calculated for all patients with data available; patients with missing data were excluded. 
Switches between two agents in the same class (eg, from an SU to another SU) were considered as treatment changes.
*May contain other oral treatments.
†Including α-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose co- transporter-2 inhibitors and glucagon- like 
peptide-1 receptor agonists.
DPP- 4i, dipeptidyl peptidase-4 inhibitor; MET, metformin; SU, sulphonylurea.
odds of metformin discontinuation were increased in 
patients who had experienced a major hypoglycaemic 
event or had a history of microvascular complications. 
The odds of metformin discontinuation were decreased 
in patients with a HbA1c level ≥7.0% (53 mmol/mol) who 
were prescribed first- line metformin monotherapy. The 
odds of discontinuing metformin monotherapy were also 
lower in patients from Africa than in those from Europe. 
Among patients who received first- line metformin as a 
combination therapy, the odds of metformin discontin-
uation were higher in patients who did not have health 
insurance than in those who did. No significant differ-
ences were observed across regions in the odds of discon-
tinuing metformin as a combination therapy. The odds of 
metformin discontinuation varied substantially between 
countries as described by the MOR, used to assess the 
association between a patient’s country of residence and 
the discontinuation of metformin treatment. Country was 
shown to be associated with metformin discontinuation in 
patients prescribed first- line metformin as a monotherapy 
(MOR: 2.55) and as part of a combination therapy (MOR: 
2.58).
DIsCussIOn
DISCOVER is a global, prospective study programme 
that assesses disease management, treatment patterns 
and clinical outcomes in patients with type 2 diabetes 
initiating second- line glucose- lowering therapy. This 
analysis of baseline data from DISCOVER showed that, 
of the patients who had received metformin as a first- 
line therapy, 84.9% continued with metformin as part 
of the second- line treatment. Nevertheless, a substan-
tial proportion of patients (15.1%) received second- 
line therapy without metformin, a higher percentage 
than would be expected if adhering to current clinical 
guidelines.3
Surprisingly, 14.1% of patients who received first- 
line metformin monotherapy discontinued metformin, 
despite guidelines recommending add- on glucose- 
lowering drugs when metformin monotherapy fails to 
control glycaemia.3 6 11 However, it is important to note 
that lack of efficacy is not the only reason for changing 
from first- line to second- line therapy. Previous studies 
have reported nausea, diarrhoea, stomach discomfort 
and a metallic taste in the mouth as potential adverse 
effects of metformin treatment,12 which may lead to 
metformin discontinuation. In our analyses, adverse 
effects were stated as a reason for changing from first- line 
therapy in a higher proportion of patients who discon-
tinued (16.8%) than continued metformin (3.4%). This 
may partly explain the large proportion of patients who 
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Table 3 First- line and second- line therapies in patients receiving metformin (as monotherapy or as part of a combination 


















First- line therapy with MET
  MET monotherapy 678 (87.1) 1543 (85.8) 1496 (49.0) 2509 (82.1) 1055 (58.0) 1207 (90.5) 8488 (71.7)
  MET combination therapy 100 (12.9) 256 (14.2) 1556 (51.0) 546 (17.9) 764 (42.0) 127 (9.5) 3349 (28.3)
   MET+SU 73 (9.4) 135 (7.5) 1045 (34.2) 297 (9.7) 521 (28.6) 68 (5.1) 2139 (18.1)
   MET+DPP- 4i 1 (0.1) 94 (5.2) 123 (4.0) 109 (3.6) 130 (7.1) 32 (2.4) 489 (4.1)
   MET+SU+DPP- 4i 1 (0.1) 14 (0.8) 97 (3.2) 29 (0.9) 70 (3.8) 6 (0.4) 217 (1.8)
   MET+other(s)* 25 (3.2) 13 (0.7) 291 (9.5) 111 (3.6) 43 (2.4) 21 (1.6) 504 (4.3)
Second- line therapy with 
MET
724 (93.1) 1629 (90.6) 2424 (79.4) 2547 (83.4) 1610 (88.5) 1121 (84.0) 10 055 (84.9)
  MET monotherapy 4 (0.5) 5 (0.3) 16 (0.5) 4 (0.1) 5 (0.3) 1 (0.1) 35 (0.3)
  MET combination therapy 720 (92.5) 1624 (90.3) 2408 (78.9) 2543 (83.2) 1605 (88.2) 1120 (84.0) 10 020 (84.6)
   MET+SU 452 (58.1) 534 (29.7) 729 (23.9) 478 (15.6) 243 (13.4) 306 (22.9) 2742 (23.2)
   MET+DPP- 4i 20 (2.6) 557 (31.0) 486 (15.9) 926 (30.3) 604 (33.2) 547 (41.0) 3140 (26.5)
   MET+SU+DPP- 4i 1 (0.1) 62 (3.4) 329 (10.8) 132 (4.3) 369 (20.3) 27 (2.0) 920 (7.8)
   MET+insulin† 67 (8.6) 105 (5.8) 107 (3.5) 269 (8.8) 116 (6.4) 9 (0.7) 673 (5.7)
   MET+other(s)* 180 (23.1) 366 (20.3) 757 (24.8) 738 (24.2) 273 (15.0) 231 (17.3) 2545 (21.5)
Second- line therapy without 
MET
54 (6.9) 170 (9.4) 628 (20.6) 508 (16.6) 209 (11.5) 213 (16.0) 1782 (15.1)
  SU monotherapy 21 (2.7) 23 (1.3) 82 (2.7) 163 (5.3) 27 (1.5) 45 (3.4) 361 (3.0)
  DPP- 4i monotherapy 3 (0.4) 65 (3.6) 130 (4.3) 134 (4.4) 62 (3.4) 88 (6.6) 482 (4.1)
  Other monotherapy* 2 (0.3) 36 (2.0) 253 (8.3) 91 (3.0) 35 (1.9) 51 (3.8) 468 (4.0)
  Insulin† 18 (2.3) 24 (1.3) 42 (1.4) 44 (1.4) 17 (0.9) 3 (0.2) 148 (1.3)
  Other combinations 
without MET
10 (1.3) 22 (1.2) 121 (4.0) 76 (2.5) 68 (3.7) 26 (1.9) 323 (2.7)
Data are reported as n (%). Percentages were calculated for all patients with data available; patients with missing data were excluded. Countries 
were grouped according to the WHO regional classification (Africa: Algeria and South Africa; Americas: Argentina, Brazil, Canada, Colombia, Costa 
Rica, Mexico and Panama; South- East Asia: India and Indonesia; Europe: Austria, Czech Republic, Denmark, France, Italy, Netherlands, Norway, 
Poland, Russia, Spain, Sweden and Turkey; Eastern Mediterranean: Bahrain, Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia and 
United Arab Emirates; Western Pacific: Australia, Japan, Malaysia, South Korea and Taiwan).
*Including α-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose co- transporter-2 inhibitors and glucagon- like peptide-1 receptor 
agonists.
†May contain other oral treatments.
DPP- 4i, dipeptidyl peptidase-4 inhibitor; Med, Mediterranean; MET, metformin; SU, sulphonylurea.
Factors associated with the discontinuation of 
metformin as a second- line therapy varied between 
patients prescribed first- line metformin as a monotherapy 
and those receiving it as a combination therapy. Among 
patients who had received first- line metformin as part of a 
combination therapy, the odds of metformin discontinu-
ation were higher in those with no health insurance than 
in those who had health insurance. Because the cost of 
metformin is relatively low compared with other glucose- 
lowering therapies, this is unlikely to be a key reason for 
treatment discontinuation in uninsured patients. Patients 
with a history of CKD were also more likely to discon-
tinue the metformin therapy than those without CKD. In 
accordance with this, the prevalence of CKD in our study 
population at baseline was higher in patients initiating 
a second- line therapy without metformin than in those 
continuing treatment with metformin. This is in line with 
current guidelines that recommend against prescribing 
metformin to patients who have an estimated glomerular 
filtration rate (eGFR) lower than 30 mL/min/1.73 m2 
(ie, stage 4 or stage 5 CKD), and recommend decreasing 
the dose for patients with mild- to- moderate renal 
impairment (eGFR 30 to 59 mL/min/1.73 m2, stage 3 
CKD).3 6 13–15 However, in a recent phase 1 trial in patients 
with type 2 diabetes and stage 4 CKD, treatment with low- 
dose metformin was not associated with adverse safety 
outcomes,16 suggesting that metformin discontinuation 
may not be necessary for these patients.
The proportions of patients who discontinued 
metformin varied considerably across study regions, from 
6.9% in Africa to 20.6% in South- East Asia. Despite this 
variation, region was not associated with a significantly 
increased chance of discontinuing metformin in the 
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Table 4 Reasons cited by physicians for changing therapy in patients receiving metformin (as monotherapy or as part of a 
combination treatment) as a first- line therapy, for patients receiving a second- line therapy with or without metformin
Reason for changing from first- line 
therapy at baseline
Patients who went on to 
receive second- line therapy 
with MET n=10 055 (84.9)
Patients who went on to 
receive second- line therapy 




Lack of efficacy 8928 (91.5) 1257 (72.7) 10 185 (88.7)
Hypoglycaemia 156 (1.6) 21 (1.2) 177 (1.5)
Weight gain 628 (6.4) 56 (3.2) 684 (6.0)
Adverse effects 331 (3.4) 291 (16.8) 622 (5.4)
Developed acute disease 41 (0.4) 27 (1.6) 68 (0.6)
Developed chronic disease 27 (0.3) 81 (4.7) 108 (0.9)
Affordability 98 (1.0) 4 (0.2) 102 (0.9)
Inability to self- administer 13 (0.1) 2 (0.1) 15 (0.1)
Patient request 127 (1.3) 61 (3.5) 188 (1.6)
Poor adherence 182 (1.9) 40 (2.3) 222 (1.9)
Patient convenience 164 (1.7) 30 (1.7) 194 (1.7)
Prescriber access 65 (0.7) 4 (0.2) 69 (0.6)
Drug interaction 3 (<0.1) 8 (0.5) 11 (0.1)
Physician preference 620 (6.4) 113 (6.5) 733 (6.4)
Missing 300 54 354
Data are reported as n (%). Several reasons could be selected for each patient. Percentages were calculated for all patients with data 
available; patients with missing data were excluded. Overall, data were available for 11 483 patients (9755 and 1728 patients who received 
second- line therapy with and without MET, respectively, after exclusion of missing data).
MET, metformin.
who had received first- line metformin monotherapy 
were less likely to discontinue metformin than patients 
from Europe. However, as shown by the MOR, country- 
level variation was associated with a higher chance of 
discontinuing metformin, suggesting that the differences 
in the proportions of patients prescribed a second- line 
treatment without metformin are mainly due to country- 
level rather than regional variation. A previous study of 
treatment patterns across five European countries also 
found substantial variation in second- line treatment 
choice between countries, possibly reflecting differences 
in local treatment guidelines.17 Country- level variation 
may also be explained by differences in the availability 
and affordability of different glucose- lowering drugs. A 
study published in 2018 found that metformin availability 
ranged between 100% in high- income countries to 64.7% 
in low- income countries.18 However, the availability of 
metformin in low- income countries was still higher than 
that of other glucose- lowering drugs such as insulin, avail-
able to only 10.3% of patients. The study also estimated 
that while 26.9% of patients from low- income countries 
could not afford metformin, 63.0% were unable to afford 
insulin, showing an association between both affordability 
and accessibility and the use of diabetes medications.
To our knowledge, the effect of metformin discon-
tinuation on patient outcomes when initiating a 
second- line glucose- lowering therapy have not been 
extensively studied. A retrospective study of electronic 
medical records in the USA showed that metformin 
discontinuation in patients with declining renal func-
tion was associated with weight gain and increased risk of 
hypoglycaemia.19 This is likely explained by the fact that 
most of these patients switched from metformin mono-
therapy to a sulphonylurea or insulin;19 these switches 
were observed in approximately one- third of DISCOVER 
patients who were using metformin monotherapy, regard-
less of their renal function. Future analyses of DISCOVER 
follow- up data may provide useful insights into the asso-
ciation between metformin discontinuation and clinical 
outcomes.
strengths and limitations
The key strengths of the DISCOVER study programme 
include the large number of participating countries, sites 
and patients, as well as the inclusion of many countries 
for which little or no data on the treatment of patients 
with type 2 diabetes are currently available. Data were 
collected using a standardised case report form, thereby 
allowing direct comparison between countries and 
regions. In addition, the wide diversity of sites and special-
ities of investigators helps to provide as inclusive a view 
as possible of the variety of healthcare settings across the 
world.
As previously reported, some limitations of the 
DISCOVER study should be considered.7 In accordance 
with the observational nature of the study, the protocol 
did not mandate the collection and recording of study 
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Figure 1 Variables associated with metformin discontinuation in patients receiving metformin (A) as monotherapy and (B) as 
part of a combination as first- line therapy. ORs were calculated using a hierarchical logistic regression model, with country as a 
random effect and adjusted for all variables in the figure. BMI, body mass index; HbA1c, glycated haemoglobin.
for some patients. However, missing data for variables 
such as HbA1c and cholesterol levels reflect real- world 
clinical practice and thereby enable DISCOVER data to 
be used to examine how differences in clinical practice 
across and within countries affect disease management 
and outcomes. As for any observational study, our find-
ings should also be interpreted in the context of potential 
residual confounding. Although the multivariate analyses 
were adjusted for a number of covariates, other variables 
for which data were not collected (eg, detailed informa-
tion about insurance coverage, access to treatments and 
study site funding) could also be associated with the odds 
of metformin discontinuation.
Finally, DISCOVER sites were selected to optimise 
diversity in each country, but it was not always possible 
to achieve full representativeness of the general patient 
population at a country, regional and global level. Reasons 
for this include a lack of comprehensive country- level 
data on the types of sites and physicians treating patients 
with type 2 diabetes before the start of the study, the small 
total number of sites in some countries and reduced 
participation of rural and primary care centres because of 
infrastructural and site capability limitations.20 The result 
may be an over- representation of more advanced treat-
ment in the urban and secondary care centres, potentially 
leading to an overestimation of the quality of care in some 
countries as well as to an over- representation of patients 
with more advanced disease and comorbidities.
Conclusion
In conclusion, a substantial proportion of DISCOVER 
patients who were prescribed first- line metformin 
discontinued therapy; the proportions of patients who 
discontinued metformin therapy differed between study 
regions. Most of these patients subsequently received a 
non- insulin monotherapy at second line, in contradic-
tion to international guidelines and potentially leaving 
them at an increased risk of hyperglycaemia and associ-
ated adverse outcomes. Differences in second- line treat-
ment choice between countries could be explained by 
local treatment availability and/or affordability, or by 
differences in local guidelines and practices. Further 
analyses from the DISCOVER study will build on the data 
presented here, to provide a comprehensive picture of 
treatment patterns and outcomes from second- line to 
later- line therapies across a variety of healthcare settings.
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